Gosogliptin
This oral antidiabetic drug belongs to the DPP-4 inhibitor (gliptin) class, which works by blocking the enzyme that breaks down the incretin hormones GLP-1 and GIP. By preserving these hormones, it stimulates insulin release after meals and reduces glucagon in a glucose-dependent manner, lowering blood sugar with a low risk of hypoglycemia. It is used to treat type 2 diabetes.
Molekularmasse
366,4000 g/mol
LogP
0,60
TPSA
64,60 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
2D-Struktur
Cite this structure
Embed this structure
SMILES
O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
InChI
InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
Molecular Formula
C17H24F2N6O
HBD / HBA
1 / 8
Rotierbare Bindungen
3
Schwere Atome
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This oral antidiabetic drug belongs to the DPP-4 inhibitor (gliptin) class, which works by blocking the enzyme that breaks down the incretin hormones GLP-1 and GIP. By preserving these hormones, it stimulates insulin release after meals and reduces glucagon in a glucose-dependent manner, lowering blood sugar with a low risk of hypoglycemia. It is used to treat type 2 diabetes.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Gosogliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL515387. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11516136. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gosogliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gosogliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gosogliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gosogliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gosogliptin"></drugfyi-drug>